This heterogeneity is reflected in signature breast cancer receptors and biomarkers expression: although some of the prominent biomarkers from each of the PAM-50 subtypes are present across the 32 breast cancer lineages analyzed by single-cell sequencing, expression of clinically relevant genes, such as HER2, can vary greatly within a cell population [75]. This evidence concerns the gene ERBB2 and breast cancer.